Download MendeleyIsoform-selective TGF-beta 3 inhibition for systemic sclerosis.
Sun, T., Vander Heiden, J.A., Gao, X., Yin, J., Uttarwar, S., Liang, W.C., Jia, G., Yadav, R., Huang, Z., Mitra, M., Halpern, W., Bender, H.S., Brightbill, H.D., Wu, Y., Lupardus, P., Ramalingam, T., Arron, J.R.(2024) Med 5: 132-147.e7
- PubMed: 38272035
- DOI: https://doi.org/10.1016/j.medj.2023.12.011
- Primary Citation of Related Structures:
8V52 - PubMed Abstract:
Transforming growth factor β (TGF-β) is implicated as a key mediator of pathological fibrosis, but its pleiotropic activity in a range of homeostatic functions presents challenges to its safe and effective therapeutic targeting. There are three isoforms of TGF-β, TGF-β1, TGF-β2, and TGF-β3, which bind to a common receptor complex composed of TGF-βR1 and TGF-βR2 to induce similar intracellular signals in vitro. We have recently shown that the cellular expression patterns and activation thresholds of TGF-β2 and TGF-β3 are distinct from those of TGF-β1 and that selective short-term TGF-β2 and TGF-β3 inhibition can attenuate fibrosis in vivo without promoting excessive inflammation. Isoform-selective inhibition of TGF-β may therefore provide a therapeutic opportunity for patients with chronic fibrotic disorders.
Organizational Affiliation:
Department of Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: sun.tianhe@gene.com.
